Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

NCT06179160 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT06179160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06179160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Lead sponsor
Incyte Corporation
Phase
Phase 1
Overall status
Recruiting
Start date
January 4, 2024
Completion date
January 1, 2027
Enrollment
710 (estimated)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors